QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
NASDAQ:ARWR

Arrowhead Pharmaceuticals - ARWR Stock Forecast, Price & News

$45.45
-1.57 (-3.34%)
(As of 08/9/2022 12:00 AM ET)
Add
Compare
Today's Range
$44.90
$46.84
50-Day Range
$27.79
$47.02
52-Week Range
$26.81
$84.83
Volume
834,781 shs
Average Volume
793,806 shs
Market Capitalization
$4.81 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$70.83

Arrowhead Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
55.8% Upside
$70.83 Price Target
Short Interest
Healthy
4.83% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.57
Upright™ Environmental Score
News Sentiment
-0.06mentions of Arrowhead Pharmaceuticals in the last 14 days
Based on 11 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.03) to ($1.65) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.17 out of 5 stars

Medical Sector

507th out of 1,098 stocks

Pharmaceutical Preparations Industry

239th out of 536 stocks

ARWR stock logo

About Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.

Arrowhead Pharmaceuticals Stock Performance

Shares of NASDAQ:ARWR traded down $1.57 during trading hours on Tuesday, reaching $45.45. 834,781 shares of the stock were exchanged, compared to its average volume of 793,806. The firm has a market capitalization of $4.81 billion, a price-to-earnings ratio of -30.72 and a beta of 1.37. The company has a debt-to-equity ratio of 0.16, a quick ratio of 3.37 and a current ratio of 3.37. Arrowhead Pharmaceuticals has a 52 week low of $26.81 and a 52 week high of $84.83. The stock's fifty day simple moving average is $37.58 and its 200 day simple moving average is $41.73.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Rating) last announced its earnings results on Thursday, August 4th. The biotechnology company reported ($0.68) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.17). The firm had revenue of $32.41 million for the quarter, compared to the consensus estimate of $52.61 million. Arrowhead Pharmaceuticals had a negative return on equity of 36.05% and a negative net margin of 61.58%. Arrowhead Pharmaceuticals's revenue for the quarter was down 29.4% on a year-over-year basis. During the same quarter last year, the business posted ($0.29) EPS. Sell-side analysts predict that Arrowhead Pharmaceuticals will post -1.03 EPS for the current year.

Wall Street Analyst Weigh In

ARWR has been the topic of several research analyst reports. The Goldman Sachs Group upped their price objective on Arrowhead Pharmaceuticals from $58.00 to $65.00 and gave the company a "buy" rating in a research note on Monday. Piper Sandler dropped their price objective on Arrowhead Pharmaceuticals from $89.00 to $72.00 in a research note on Wednesday, May 11th. Chardan Capital upped their price objective on Arrowhead Pharmaceuticals from $80.00 to $82.00 in a research note on Friday. HC Wainwright restated a "buy" rating and issued a $110.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Thursday, July 14th. Finally, Robert W. Baird upgraded Arrowhead Pharmaceuticals from a "neutral" rating to an "outperform" rating and dropped their price objective for the company from $71.00 to $60.00 in a research note on Wednesday, May 11th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $70.83.

Receive ARWR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arrowhead Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ARWR Stock News Headlines

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Trading Up 7%
5 Top Biotech Stocks To Watch In July 2022
See More Headlines
Receive ARWR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arrowhead Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ARWR Company Calendar

Last Earnings
8/04/2022
Today
8/09/2022
Fiscal Year End
9/30/2022
Next Earnings (Estimated)
11/28/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ARWR
Employees
329
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$70.83
High Stock Price Forecast
$110.00
Low Stock Price Forecast
$36.00
Forecasted Upside/Downside
+55.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Net Income
$-140,850,000.00
Pretax Margin
-61.58%

Debt

Sales & Book Value

Annual Sales
$138.29 million
Book Value
$3.92 per share

Miscellaneous

Free Float
102,462,000
Market Cap
$4.81 billion
Optionable
Optionable
Beta
1.37

Key Executives

  • Dr. Christopher R. Anzalone Ph.D. (Age 53)
    CEO, Pres & Director
    Comp: $1.68M
  • Mr. Kenneth A. Myszkowski (Age 56)
    Chief Financial Officer
    Comp: $729.77k
  • Mr. Patrick O'Brien (Age 58)
    Chief Compliance Officer, Gen. Counsel & Corp. Sec.
    Comp: $733.13k
  • Dr. James C. Hamilton M.D. (Age 43)
    MBA, Sr. VP of Discovery & Translational Medicine
    Comp: $673.45k
  • Dr. Javier San Martin M.D. (Age 57)
    Chief Medical Officer
    Comp: $658.48k
  • Dr. Mark M. Davis Ph.D.
    Founder and Founder & Director of Insert Therapeutics Inc & Calando
  • Ms. Jane Davidson
    Head of HR & Admin., VP and Corp. Sec.
  • Dr. Vincent Anzalone CFA
    Head of Investor Relations & VP
  • Mr. Howard Lovy
    Director of Communications
  • Dr. Mark Seefeld (Age 68)
    Head of Toxicology & VP













ARWR Stock - Frequently Asked Questions

Should I buy or sell Arrowhead Pharmaceuticals stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arrowhead Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ARWR shares.
View ARWR analyst ratings
or view top-rated stocks.

What is Arrowhead Pharmaceuticals' stock price forecast for 2022?

5 Wall Street analysts have issued 1 year price objectives for Arrowhead Pharmaceuticals' stock. Their ARWR share price forecasts range from $36.00 to $110.00. On average, they predict the company's share price to reach $70.83 in the next twelve months. This suggests a possible upside of 56.4% from the stock's current price.
View analysts price targets for ARWR
or view top-rated stocks among Wall Street analysts.

How has Arrowhead Pharmaceuticals' stock performed in 2022?

Arrowhead Pharmaceuticals' stock was trading at $66.30 at the beginning of the year. Since then, ARWR stock has decreased by 31.7% and is now trading at $45.28.
View the best growth stocks for 2022 here
.

When is Arrowhead Pharmaceuticals' next earnings date?

Arrowhead Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, November 28th 2022.
View our ARWR earnings forecast
.

How were Arrowhead Pharmaceuticals' earnings last quarter?

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) issued its earnings results on Thursday, August, 4th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by $0.17. The biotechnology company earned $32.41 million during the quarter, compared to analyst estimates of $52.61 million. Arrowhead Pharmaceuticals had a negative trailing twelve-month return on equity of 36.05% and a negative net margin of 61.58%. The firm's revenue for the quarter was down 29.4% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.29) EPS.

What other stocks do shareholders of Arrowhead Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arrowhead Pharmaceuticals investors own include Bellicum Pharmaceuticals (BLCM), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Alliance Resource Partners (ARLP), Bank of America (BAC), Tesla (TSLA), Salesforce (CRM) and Advanced Micro Devices (AMD).

What is Arrowhead Pharmaceuticals' stock symbol?

Arrowhead Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARWR."

Who are Arrowhead Pharmaceuticals' major shareholders?

Arrowhead Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Candriam S.C.A. (0.36%), Retirement Systems of Alabama (0.31%), Swiss National Bank (0.22%), Russell Investments Group Ltd. (0.21%), Mirae Asset Global Investments Co. Ltd. (0.20%) and Banque Pictet & Cie SA (0.18%). Insiders that own company stock include Adeoye Y Olukotun, Backer Marianne De, Bruce D Given, Christopher Richard Anzalone, Douglas B Given, Douglas B Given, James C Hamilton, James Hassard, Kenneth Allen Myszkowski, Martin Javier San, Mauro Ferrari, Michael S Perry, Patrick O'brien and William D Waddill.
View institutional ownership trends
.

How do I buy shares of Arrowhead Pharmaceuticals?

Shares of ARWR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arrowhead Pharmaceuticals' stock price today?

One share of ARWR stock can currently be purchased for approximately $45.28.

How much money does Arrowhead Pharmaceuticals make?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) has a market capitalization of $4.79 billion and generates $138.29 million in revenue each year. The biotechnology company earns $-140,850,000.00 in net income (profit) each year or ($1.48) on an earnings per share basis.

How many employees does Arrowhead Pharmaceuticals have?

Arrowhead Pharmaceuticals employs 329 workers across the globe.

How can I contact Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals' mailing address is 177 E. Colorado Blvd Suite 700, Pasadena CA, 91105. The official website for the company is www.arrowheadpharma.com. The biotechnology company can be reached via phone at (626) 304-3400, via email at ir@arrowheadpharma.com, or via fax at 626-304-3401.

This page (NASDAQ:ARWR) was last updated on 8/9/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.